First Aid tailored to Knife Attacks

 This free course from ProTrainings Europe looks at the basic first aid required to treat a knife crime injury at the scene. With simple first aid techniques and fast activation of the emergency services, lives can be saved.

First aid is not difficult and very easy to learn and remember.  The course covers keeping yourself safe to different first aid subjects to give you a basic understanding of how to save a life.

The course is broken down into short videos and once you complete the course you can download your free certificate.  To support the training you will be able to download a student manual that covers many different first aid subjects and other downloads and links to support your training.

You do not need any first aid knowledge to start this course and it is suitable for all ages. We also offer a free student first aid program for all children to teach them more about different levels of first aid and CPR. 

The content of this and all our courses has been independently certified as conforming to universally accepted Continuous Professional Development (CPD) guidelines and come with a Certified CPD Statement as well as a ProTrainings Certificate and for online courses an Evidence Based Learning statement.

Occupations That Use This Course

Sample Online Certificate

  CPD Certified - 1.0 hrs (2.0 class)

https://www.protrainings.uk/courses/535-first-aid-for-knife-attacks-level-2-vtq?search_term=First+aid+for+Knife+attacks

Man stabbed in Times Square steps away from NYC New Year’s ball drop

 A man was stabbed at least eight times in Midtown, just steps away from the Times Square spot where throngs gather to ring in the new year, police said.

The bloody episode happened at around 11 a.m. Saturday near Seventh Avenue and West 40th Street, the NYPD said.

Police identified the “uncooperative” victim as a man in his 20s, who was stabbed “around eight times” about his body, an NYPD spokesperson said. Sources said he was stabbed on the street.

1of5

The victims blood on a NYPD cruiser at the scene of the stabbing.

G.N.Miller/NYPost

Blood-soaked clothing on the ground in Times Square.

G.N.Miller/NYPost

Advertisement

The victim was brought to Bellevue Hospital with non-life-threatening injuries.

G.N.Miller/NYPost

Advertisement

The victim was taken to the Bellevue Hospital with non-life-threatening injuries, cops said.

Police are looking for a suspect described as a man in his 20s who was wearing a black jacket, black pants and white sneakers, and carrying a red bag.  The attacker ran south on Seventh Avenue, authorities said.

Remnants of shocking stabbing were evident Saturday afternoon. Blood was visible near the Times Square 42nd Street station on the corner of 40th Street and Seventh and blood-soaked clothing was spotted on the ground near an NYPD cruiser, which had blood smeared on it.

NYPD at the scene of where a man was stabbed in Times Square on December 31, 2022.

G.N.Miller/NYPost

The incident occurred amid fatal stabbings and slashings being up an alarming 37% in the Big Apple this year as of mid December, NYPD data show.

https://nypost.com/2022/12/31/man-stabbed-in-times-square-near-nyc-new-years-festivities/

GSK Looking For Under-Appreciated M&A Targets, Not To Be Next Roche Or AstraZeneca

 

• GSK plc 
  GSK+0.03%+ Free Alerts
   chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding war.'
• Luke added that GSK is looking to acquire or partner with biotechs' hiding in plain sight' to expand its pipeline.
• Earlier this year, GSK acquired Sierra Oncology for $55 per share in cash, representing an approximate total equity value of $1.9 billion (£1.5 billion).
• Miels, according to Financial Times, said he was now spending far more time than usual on business development as he hopes to secure drugs that will be approved in the medium term. 
• GSK is trying to rebuild its capability in oncology after the previous management team exited the field via a 2015 deal with Novartis AG 
  NVS-0.96%+ Free Alerts
  .
• But analysts say that GSK's efforts so far have been lackluster and aggravated last month when the company had to withdraw its Blenrep drug from the U.S. market after a negative trial result. 
• Miels said there was the potential for GSK to refile for approval for Blenrep based on other studies that had yet to report results. 

https://www.benzinga.com/general/biotech/22/12/30237402/gsk-looking-for-under-appreciated-m-a-targets-not-trying-to-be-next-roche-or-astrazeneca